Hello and happy hump day, readers!
Last year, a band of health systems fed up with ever-increasing generic drug prices and a bevy of medication shortages decided they’d had enough and would take matters into their own hands. Thus Civica Rx was born. Now, the nonprofit coalition has unveiled the first treatments it will set its sights on: Antibiotics.
Civica Rx on Wednesday announced a deal with Danish generic drug maker Xellia to make forms of the injectable antibiotics vancomycin and daptomycin available to partner hospitals, which number in the hundreds. These treatments are used as antibiotics for certain patients with the most resistant forms of bacterial infections and are often in short supply, likely due to manufacturing woes.
This duo of products is just the first in a planned series of 14 treatments that Civica plans to make available to its members in the coming years. Licensing deals appear to be the primary focus at the moment–but perhaps the future could see actual independent drug development (admittedly a far more expensive and risky enterprise for a nonprofit).
Read on for the day’s news.
Livongo expands into parenthood behavioral health.
Johnson & Johnson says it can roll out 10 new drug applications by 2023. (Reuters)
THE BIG PICTURE
Alabama passes a near-total abortion ban.
Would Medicare for All really be a bad bet for business?
Here’s How Bad the Supreme Court’s App Store Decision Could Be for Apple, by Don Reisinger
Honeywell CEO on China Tariffs: ‘We’re Ready,’ by Jesse Rogala
Facebook, Twitter, Alphabet Join Global Pledge to Combat Online Hate Speech, by Helene Fouquet, Gregory Viscusi, & Bloomberg
[ceo_attribution author=”Produced by Sy Mukherjee” email=”firstname.lastname@example.org” twitter=”the_sy_guy”] Find past coverage. Sign up for other Fortune newsletters.